Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 41Terminated 21Recruiting 12Unknown 9Active not recruiting 9Withdrawn 5Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hydroxychloroquine × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡